Cabaletta Bio, Inc.
CABADrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How CABA's past catalysts played out
CABA-201
Generalized Myasthenia Gravis (gMG)
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Idiopathic Inflammatory Myopathy
DSG3-CAART
Pemphigus Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CABA-201 | Phase 3 | Generalized Myasthenia Gravis (gMG) | - | - |
CABA-201 following preconditioning with fludarabine and cyclophosphamide | Phase 3 | Idiopathic Inflammatory Myopathy | - | - |
DSG3-CAART | Phase 2 | Pemphigus Vulgaris | - | - |
Frequently asked questions
What is in Cabaletta Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cabaletta Bio, Inc.'s (CABA) pipeline across Phase 3, Phase 2. Its lead program is CABA-201 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cabaletta Bio, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Cabaletta Bio, Inc. (CABA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CABA biotech catalysts?→
Add CABA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cabaletta Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.